AVE 33.3% 0.2¢ avecho biotechnology limited

comfortable cash position at end of this year, page-2

  1. 5,796 Posts.
    lightbulb Created with Sketch. 736
    It is clear to me that the point being made is that there is no foreseeable cash raise.
    The tax rebate is huge and Esra was explaining that POH are one of the few companies that was able to claim research expenses that were carried out oversees.
    The other reason is that the change in strategy of aiming for a deal post phase II is that the money raised for the phase III will carry us a long way, probably long enough until the deal in early 2014 is complete.
    In summary - no more cash raises for POH is on the agenda.
 
watchlist Created with Sketch. Add AVE (ASX) to my watchlist
(20min delay)
Last
0.2¢
Change
-0.001(33.3%)
Mkt cap ! $6.338M
Open High Low Value Volume
0.3¢ 0.3¢ 0.2¢ $17 5.798K

Buyers (Bids)

No. Vol. Price($)
55 95690716 0.2¢
 

Sellers (Offers)

Price($) Vol. No.
0.3¢ 59980558 19
View Market Depth
Last trade - 16.10pm 09/08/2024 (20 minute delay) ?
AVE (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.